ReviewCancers2024
Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Association between prognostic nutritional index and prognosis in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.Frontiers in nutrition · 2026Pooled it
- Identifying markers of cachexia and nutritional deficit on radical radiotherapy outcomes in lung and head and neck cancer.Current opinion in supportive and palliative care · 2026Review
- Prognostic value of gut microbiota-derived metabolites in non-small cell lung cancer: a retrospective cohort study of overall survival.Translational cancer research · 2026Article
- Prolactin as a Candidate Biomarker in Non-Small Cell Lung Cancer: Implications for Personalized Medicine and Post-Treatment Risk Stratification.Journal of personalized medicine · 2026Review
- Exploring the prognostic value of the magnesium-immune prognostic score (MIPS) in metastatic non-small cell lung cancer receiving Nivolumab.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Predictive value of combined inflammatory and coagulation markers for immune-related pneumonitis in non-small cell lung cancer patients on immunotherapy: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Machine learning-assisted classification of lung cancer: the role of sarcopenia, inflammatory biomarkers, and PET/CT anatomical-metabolic parameters.Physical and engineering sciences in medicine · 2026Article
- A comprehensive prognostic model for older patients with advanced non-small cell lung cancer receiving immunotherapy: a multicenter real-world study.Frontiers in immunology · 2026Article
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
- Prognostic value of the C-reactive protein-albumin-lymphocyte (CALLY) index in surgically treated non-small cell lung cancer.Frontiers in nutrition · 2026Article
- MLR and dMLR Predict Locoregional Control and Progression-Free Survival in Unresectable NSCLC Stage III Patients: Results from the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).Journal of clinical medicine · 2025Article
- MetaPredictomics: A Comprehensive Approach to Predict Postsurgical Non-Small Cell Lung Cancer Recurrence Using Clinicopathologic, Radiomics, and Organomics Data.Clinical nuclear medicine · 2025Article
- Article
- The value of prognostic immune-inflammatory-nutritional score in predicting survival after surgery in stage I-III non-small cell lung cancer.Journal of thoracic disease · 2025Article
- Variation in CBC-Derived Inflammatory Biomarkers Across Histologic Subtypes of Lung Cancer: Can Histology Guide Clinical Management?Diagnostics (Basel, Switzerland) · 2025Article
- Splenic index score as a predictor of outcomes in metastatic non small cell lung cancer patients treated with immune checkpoint inhibitors.Scientific reports · 2025Article
- An Emergency-deployable Albumin-enhanced NLR Derived by Machine Learning Improves Risk Stratification in Lung Cancer: A Multicenter Cohort Study.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is a common malignancy and is associated with poor survival outcomes. Biomarkers of systemic inflammation derived from blood tests collected as part of routine clinical care offer prognostic information for patients with NSCLC that may assist clinical decision making. They are an attractive tool, as they are inexpensive, easily measured, and reproducible in a variety of healthcare settings. Despite the wealth of evidence available to support them, these inflammatory biomarkers are not yet routinely used in clinical practice. In this narrative review, the key inflammatory indices reported in the literature and their prognostic significance in NSCLC are described. Key challenges limiting their clinical application are highlighted, including the need to define the optimal biomarker of systemic inflammation, a lack of understanding of the systemic inflammatory landscape of NSCLC as a heterogenous disease, and the lack of clinical relevance in reported outcomes. These challenges may be overcome with standardised recording and reporting of inflammatory biomarkers, clinicopathological factors, and survival outcomes. This will require a collaborative approach, to which this field of research lends itself. This work may be aided by the rise of data-driven research, including the potential to utilise modern electronic patient records and advanced data-analysis techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.